Inside Sangamo Therapeutics: RSU Sales Show Executive Commitment, Not Market Risk
Insightful insider RSU activity at Sangamo Therapeutics shows senior execs are committed to the gene‑editing pipeline, not quick sales—good news for long‑term investors.
4 minutes to read